<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127815">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980875</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-312-0118</org_study_id>
    <secondary_id>2013-004551-20</secondary_id>
    <nct_id>NCT01980875</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Idelalisib in Combination With Rituximab or Chlorambucil for Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Either Rituximab or Chlorambucil for Previously Untreated Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Croatia: Agency for Medicinal Product and Medical Devices</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Portugal: INFARMED, National Authority of Medicines and Health Products, IP</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of idelalisib with either rituximab or chlorambucil on
      progression-free survival (PFS) in participants with untreated chronic lymphocytic leukemia
      (CLL).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall response rate (ORR) is defined as the proportion of participants who achieve a complete or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nodal response rate</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response rate is defined as the proportion of participants who achieve a complete response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease negativity rate</measure>
    <time_frame>Week 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimal residual disease (MRD) negativity rate is defined as the proportion of subjects with MRD &lt; 10^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab for participants receiving the final dose of rituximab after the original scheduled date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Baseline to Year 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival is defined as the interval from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Idelalisib+rituximab or chlorambucil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive idelalisib for 96 weeks and rituximab for 8 weeks or chlorambucil for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idelalisib placebo+rituximab or chlorambucil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive placebo to match idelalisib for 96 weeks and rituximab for 8 weeks or chlorambucil for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Idelalisib 100 mg or 150 mg tablets administered orally twice daily</description>
    <arm_group_label>Idelalisib+rituximab or chlorambucil</arm_group_label>
    <other_name>GS-1101</other_name>
    <other_name>CAL-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 100 mg or 500 mg single-use vials administered intravenously weekly</description>
    <arm_group_label>Idelalisib+rituximab or chlorambucil</arm_group_label>
    <arm_group_label>Idelalisib placebo+rituximab or chlorambucil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorambucil</intervention_name>
    <description>Chlorambucil 2 mg tablets administered orally every other week for a total of 12 doses</description>
    <arm_group_label>Idelalisib+rituximab or chlorambucil</arm_group_label>
    <arm_group_label>Idelalisib placebo+rituximab or chlorambucil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib placebo</intervention_name>
    <description>Placebo to match idelalisib administered orally twice daily</description>
    <arm_group_label>Idelalisib placebo+rituximab or chlorambucil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Documented diagnosis of B-cell CLL, with diagnosis established according to
             International Workshop on Chronic Lymphocytic Leukemia (IWCLL)

          -  No prior therapy for CLL other than corticosteroids for disease complications.

          -  CLL that warrants treatment

          -  Presence of measurable lymphadenopathy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

        Exclusion Criteria

          -  Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
             transformation)

          -  Known presence of myelodysplastic syndrome

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             randomization

          -  Ongoing liver injury

          -  Ongoing drug-induced pneumonitis

          -  Ongoing inflammatory bowel disease

          -  History of prior allogeneic bone marrow progenitor cell or solid organ
             transplantation

          -  Ongoing immunosuppressive therapy other than corticosteroids

          -  Concurrent participation in another therapeutic clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Dubowy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ori Yellin</last_name>
    <email>Ori.Yellin@gilead.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Guillet</last_name>
    <email>Susan.Guillet@gilead.com</email>
  </overall_contact_backup>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chlorambucil</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
